Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease (Journal article)

Pakas, I./ Ioannidis, J. P./ Malagari, K./ Skopouli, F. N./ Moutsopoulos, H. M./ Vlachoyiannopoulos, P. G.


OBJECTIVE: To evaluate the safety and efficacy of monthly intravenous pulses of cyclophosphamide (CP) in combination with low or high doses of prednisolone in patients with systemic sclerosis (SSc) related interstitial lung disease (ILD) with FVC < 70% of predicted. METHODS: An open label, non-parallel arm study, performed in the rheumatology outpatient clinic of a university hospital. Twenty-eight patients with SSc related ILD were evaluated. Endpoint evaluations included the evolution of high resolution computed tomography, pulmonary function tests, skin involvement and dyspnea over 12 months. Patients were treated with monthly IV CP in combination with prednisolone at low (< 10 mg/day; n = 12) or high doses (1 mg/kg/day for 4 weeks, then reducing the prednisolone by 5 mg/day on alternating days each 2 weeks; n = 16). RESULTS: In the low dose steroid group, no improvement was seen for any endpoint at 6 and 12 months of followup. In the high dose steroid group, at 12 months there was significant improvement in the percentage of "ground glass" parenchymal lung involvement (-5.7%; p = 0.003), as well as in the percentage of predicted FVC (12.4%; p < 0.001), the percentage of predicted DLCO (7.3%; p = 0.029), the percentage of skin involvement (-5.4%; p = 0.01), and the severity of dyspnea (p = 0.012). Substantial improvement was seen as early as 6 months. One patient (low dose group) died from ILD. CONCLUSION: A combination of IV pulse CP with high doses of prednisolone shows promising efficacy in improving the clinical, physiological, and radiological evolution of SSc related ILD with reversal of the underlying alveolitis.
Institution and School/Department of submitter: Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής
Keywords: Ambulatory Care,Anti-Inflammatory Agents/analysis/*therapeutic use,Cyclophosphamide/*therapeutic use,Dose-Response Relationship, Drug,Drug Therapy, Combination,Dyspnea/drug therapy/etiology/physiopathology,Female,Hospitals, University,Humans,Immunosuppressive Agents/*therapeutic use,Injections, Intravenous,Lung/physiopathology/radiography,Male,Middle Aged,Prednisolone/administration & dosage/*therapeutic use,Prospective Studies,Pulmonary Fibrosis/complications/*drug therapy/physiopathology,Pulse Therapy, Drug,Respiratory Function Tests,Scleroderma, Systemic/complications/*drug therapy/physiopathology,Tomography, X-Ray Computed,Treatment Outcome
URI: http://olympias.lib.uoi.gr/jspui/handle/123456789/22655
ISSN: 0315-162X
Link: http://www.ncbi.nlm.nih.gov/pubmed/11842824
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
There are no files associated with this item.



 Please use this identifier to cite or link to this item:
http://olympias.lib.uoi.gr/jspui/handle/123456789/22655
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.